Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00480532 · ClinicalTrials.gov registry record · NA
A Study of Continuous Oral Contraceptives and Doxycycline
A NA study of Contraceptives, Oral, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 131
- Enrollment target
- 2
- Study locations
NCT00480532: Completed NA study of Contraceptives, Oral, sponsored by Oregon Health and Science University.
NCT00480532 is a NA study of Contraceptives, Oral that has completed, run by Oregon Health and Science University. The registered enrollment target is 131 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00480532, a NA study of Contraceptives, Oral, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 131 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only contraception but has not been studied in combined hormonal contraception.
Primary Outcome
number of days of bleeding and spotting, self reported on calendar
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline
- DRUG Oracea
- DRUG Lybrel
- DRUG Doxycycline 100bid x5 days at the time of bleeding
Study Locations (2)
Hawaii
- University of Hawaii (UH) - Honolulu
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2007-05 |
| Est. Completion | 2011-05 |
| Phase | NA |
What the finished NCT00480532 record still lists
NCT00480532 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Contraceptives, Oral appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT00480532 reports a single indexed study location in Hawaii, Oregon.
Frequently Asked Questions
What is clinical trial NCT00480532 about?
NCT00480532 is a clinical study titled "A Study of Continuous Oral Contraceptives and Doxycycline". The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug...
What is the current status of trial NCT00480532?
This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2007-05. Estimated completion is 2011-05.
What conditions does trial NCT00480532 study?
This clinical trial studies the following conditions: Contraceptives, Oral.
What interventions are being tested in trial NCT00480532?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG), Oracea (DRUG), Lybrel (DRUG), Doxycycline 100bid x5 days at the time of bleeding (DRUG).
Who is sponsoring clinical trial NCT00480532?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00480532 being conducted?
This trial has 2 study locations across Hawaii, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00480532's enrollment target sits among peer trials
131 732nd of 2000 higher than 1,268 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia